1. Home
  2. CMCO vs AUPH Comparison

CMCO vs AUPH Comparison

Compare CMCO & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Columbus McKinnon Corporation

CMCO

Columbus McKinnon Corporation

HOLD

Current Price

$14.55

Market Cap

609.1M

Sector

Industrials

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$13.95

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMCO
AUPH
Founded
1875
1993
Country
United States
Canada
Employees
N/A
N/A
Industry
Construction/Ag Equipment/Trucks
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
609.1M
1.6B
IPO Year
2002
2014

Fundamental Metrics

Financial Performance
Metric
CMCO
AUPH
Price
$14.55
$13.95
Analyst Decision
Buy
Buy
Analyst Count
2
4
Target Price
$21.00
$17.25
AVG Volume (30 Days)
414.0K
903.8K
Earning Date
05-08-2026
01-01-0001
Dividend Yield
1.82%
N/A
EPS Growth
N/A
5075.00
EPS
0.30
2.07
Revenue
$936,240,000.00
$283,055,000.00
Revenue This Year
$19.73
$17.35
Revenue Next Year
$82.91
$15.66
P/E Ratio
$51.17
$6.95
Revenue Growth
3.27
20.38
52 Week Low
$11.78
$6.83
52 Week High
$24.40
$16.54

Technical Indicators

Market Signals
Indicator
CMCO
AUPH
Relative Strength Index (RSI) 20.39 41.68
Support Level $13.92 $13.52
Resistance Level $16.02 $15.23
Average True Range (ATR) 0.91 0.57
MACD -0.43 0.00
Stochastic Oscillator 1.52 24.42

Price Performance

Historical Comparison
CMCO
AUPH

About CMCO Columbus McKinnon Corporation

Columbus McKinnon Corp is a designer, manufacturer, and marketer of intelligent motion solutions, including motion control products, technologies, automated systems, and services that efficiently and ergonomically move, lift, position, and secure materials. Its key products include hoists, crane components, precision conveyors, actuators, rigging tools, light rail workstations, and digital power and motion control systems. The company's targeted market verticals include general industries, process industries, industrial automation, and e-commerce/supply chain/warehousing among others. Geographically, the company generates a majority of its revenue from the United States and the rest from Germany, Canada, Asia Pacific, Latin America, Europe, the Middle East, and Africa.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: